

If you are unable to see the message below, [click here to view online](#).



Are you listed in our online provider directory? Click here to [enrol](#).



Read the latest issues of the SAJHIVMED and HIV Nursing Matters:



Members login here.



Not a member? [Join today!](#)

[Upcoming CME Meetings:](#)

**WITBANK – New CME Site LAUNCH 13 June**

**1) Atomo Rapid HIV Test:** A short presentation by Atomo Diagnostics

**2) HIV & Fertility:** Current challenges and some solutions by Dr Vivian Black

DURBAN

## SA HIV CLINICIANS SOCIETY NEWSLETTER June 2013

### Statement on Efavirenz

The Society's Child and Adolescent committee has issued a [statement](#) on the use of Efavirenz (EFV) in children less than 3 years of age. The statement is in response to FDA's approval of an expanded indication for EFV to include children from 3 months of age and weighing at least 3.5kgs. The Society does not recommend the routine use of EFV in children under 3 years of age or less than 10kg due to toxicity and efficacy concerns. Please read the statement [online](#) and direct questions or comments to [child\\_adolescent@sahivsoc.org](mailto:child_adolescent@sahivsoc.org).

### Managing HIV and TB resistance

We are pleased to include a copy of the '[HIV and TB Resistance & Clinical Management Case Book](#)' along with the June issue of SAJHIVMED. Given the challenges of HIV and TB drug resistance confronting health care workers in Africa, the case book uses a case-based learning approach to provide information on how drug resistance develops in HIV and TB; provide in-depth information on interpreting resistance tests and the new diagnostic tests available; and how to offer comprehensive care for patients. Authored by Dr Theresa Rossouw (UP) and Drs Richard Lessels and Tulio de Oliveira (African Centre for Health and Population Studies), the book is published under an open access licence and a PDF can be downloaded [here](#).



### New issues of the SAJHIVMED and HIV Nursing Matters

The June issue of the Southern African Journal of HIV Medicine is available [online](#) and in the post. This issue features updated [guidelines for the prevention, diagnosis and management of cryptococcal meningitis among HIV-infected persons](#); original research including [challenges to delivering quality care in a PMTCT programme](#), a [suicide risk screening scale for HIV-infected persons in the immediate post-diagnosis period](#), and [parental presence within households and the impact on ART](#); and case studies covering [AIDS-related KS and pregnancy, when to retest in pregnancy](#), and [progressive HIV infection in the presence of a raised CD4+ count](#).

This issue also includes our first "clinical challenge", a regular section where we present complex, real-world HIV medicine cases to two experienced clinicians working in very different environments, and ask them to describe the approach that they would take if they saw the case in their local hospital setting. In our first edition, [a patient with deteriorating liver function is presented by Prof. Francois Venter and Dr Ntsakisi Masingi, and then discussed by Dr Sarah Stacey in Johannesburg and Dr Sarah Fidler in London](#).

The June issue of [HIV Nursing Matters](#) will be released at the [6th SA AIDS Conference](#). This issue is focussed on family and community-centred care.

### Are you up for the challenge? New clinical case study online

A new clinical case study is available on our website. The case study, [The Diagnosis and Management of Second-line Antiretroviral Treatment Failure](#), is our most challenging yet – it has received a rating of 4 out of 5 on degree of difficulty (5 being most difficult). The study contains information on interpreting genotypic resistance tests, with emphasis on resistance to second-line ARV regimens containing protease inhibitors, adverse events and appropriate choices for a third-line regimen. A post-test questionnaire is available

**DURBAN**  
AIDS CONFERENCE WEEK  
18 June – Hilton Hotel  
30 years since the discovery  
of HIV: remaining challenges  
and future science  
Prof Salim Karim

**EAST LONDON**  
19 June  
HIV: Getting to the  
heart of the Matter  
Dr WW Lubbe

**PORT ELIZABETH**  
26 June  
New ARV Guidelines  
and FDC Rollout  
Dr Michelle Moorhouse

**CAPE TOWN**  
28 June  
Lipodystrophy – The  
evidence of when to change  
treatment  
Dr Siphso Dlamini

For more information about  
our CME meetings, please  
contact Natalie Martyn at  
[natalie@sahivsoc.org](mailto:natalie@sahivsoc.org)  
or visit our [website](http://www.sahivsoc.org).



## Fixed-dose combination (FDC) letter to private practitioners

In late April the Society sent a [letter to private practitioners outlining the phased roll-out of FDCs in the public sector](#). Presently, only patients who meet the following criteria are eligible for FDCs in the public sector:

Priority 1: All HIV positive patients newly initiating ART (adults, adolescents and pregnant women, regardless of CD4 count) who do not have contraindications to the FDC component drugs; and

Priority 2: HIV-positive pregnant women and breastfeeding mothers currently stable on lamivudine (3TC), tenofovir (TDF) and efavirenz (EFV).

If you are approached by public sector patients who **do not** fall into priority 1 or 2 for FDCs, it is critical that they patient understand that if they are switched to the FDC in the private sector and then return to the public sector for healthcare it may not be possible for them to remain on the FDC. We appeal to you to help manage the expectations of patients and the priorities of public healthcare facilities during this transition period. If you have any questions about the roll out of FDCs, please contact us at [sahivsoc@sahivsoc.org](mailto:sahivsoc@sahivsoc.org).

time regimen. A post-test questionnaire is available after the case study, which is worth 4 CPD points (please note only members in good standing are eligible to receive CPD points). Challenge yourself and earn CPD credit by completing the case study today.

## Guidelines

The latest Society guidelines, [guidelines for the prevention, diagnosis and management of cryptococcal meningitis among HIV-infected persons](#), were the first Society guidelines that underwent a "consultation period" prior to finalisation. During the consultation period members were able to submit comments on the guideline; we received many substantial comments that resulted in changes to the final document. Thank you to those who took the time to read the guideline and provide feedback. All future Society guidelines will include a similar consultation period. The next guideline to be published will be on mental health; we will send a notice to the membership when the document is ready for review. Other guidelines in the queue include an update to the Society's guidelines on [antiretroviral therapy management for displaced populations](#) (published in 2007) and [post-exposure prophylaxis guidelines](#) (published in 2008).

If you have any questions about guidelines or recommendations for guideline topics please send us an email at [sahivsoc@sahivsoc.org](mailto:sahivsoc@sahivsoc.org).

## ISENTRESS™ 400 mg tablets on state antiretroviral tender

For the first time since the start of the public sector ARV program, ARVs for resistant patients are included on the national ART tender. MSD is proud to share the following product information on ISENTRESS™ (raltegravir) with health care providers:

**Brand name:** ISENTRESS™ tablets  
**Active ingredient:** Raltegravir  
**Delivered price:** R532,73 (VAT Incl.)  
**Unit pack:** 60's  
**Shipper pack:** 1  
**Lead time:** 21 days  
**Minimum order quantity:** 1x60's  
**National stock number:** 18-187-4441 (CO)

ISENTRESS™ is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

Click here to read MSD's full "[Dear Healthcare Professional](#)" letter on ISENTRESS™.



## Draft regulations on research on human subjects

The Department of Health has released draft regulations to the National Health Act on "[Research on Human Subjects](#)". These regulations cover non-therapeutic research with minors and will impact HIV-and TB-related social science research in South Africa. The Society is working with partners to provide comments to the regulations; the deadline for comment is 28 July 2013.

## Satellite Symposium: New Challenges in the Management of HIV in 2013 and Beyond

MSD is pleased to invite you to attend a live webcast, [New Challenges in the Management of HIV in 2013 and Beyond](#), from IAS 2013 on Tuesday, 02 July, 12:30- 14:30 CAY. The webcast will review important findings around the challenges of managing ARV long-term toxicity, the pros and cons of NRTI sparing regimens and managing drug-drug interactions.

Participants will have the opportunity to listen to leading HIV specialists and ask questions at the conclusion of the presentation.

May 2013

Dear Healthcare Professional,

**ISENTRESS™ 400 mg tablets on National Department of Health Antiretroviral State Tender**

In 2012, South Africa's Minister of Health announced the award of a new antiretroviral (ARV) tender that, for the first time since the start of the public sector ARV program, includes ARVs for resistant patients, inclusive of ISENTRESS™ (raltegravir).

For your convenience, we are providing you with the following product information:

Brand Name	Active Ingredient	Delivered Price (Incl. VAT)	Unit Pack	Shipper Pack	Lead Time (Days)	Minimum Order Quantity	National Stock Number
ISENTRESS™ tablets	Raltegravir	R522.73	60's	1	21	1 x 60's	19-187-4441(C0)

Contract Number: 19F13-2013 ARV (period 1st January 2013 to 31st December 2014)

ISENTRESS™ is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

The recommended dosage of ISENTRESS™ is 400 mg administered orally, twice daily with or without food. ISENTRESS™ is to be given in a combination regimen with other antiretroviral agents.<sup>1</sup>

Our highly experienced team is dedicated to providing you with not only a highly professional service, but access to the latest clinical and therapeutic information. You are most welcome to contact MSD directly or any member of our team to facilitate an enquiry and we look forward to being of service to you.

Your ongoing support is highly valued.

Yours sincerely,

Justin Gandy  
ISENTRESS™ Brand and Customer Manager



## Save the Date – Society Biennial Conference 24-27 September, CTICC

Following on the success of our inaugural conference in 2012, our second SA HIV Clinicians Society Conference will take place 24-27 September 2014 at the Cape Town International Conference Centre.

Focusing on clinical content, our conference is aimed at doctors, nurses and pharmacists and will be fully CPD accredited.

Please diarise this event and keep an eye on our website: [www.sahivsoc2014.co.za](http://www.sahivsoc2014.co.za) for the latest updates.



## Recent publications and meetings

[Study finds first evidence that PrEP can reduce HIV risk among people who inject drugs; CDC to publish guidance on prescribing PrEP to IDUs in MMWR today](#)

UNAIDS: [Ending overly broad criminalisation of HIV non-disclosure, exposure and transmission: Critical scientific, medical and legal considerations](#)

Consortium for Refugees and Migrants in South Africa: [Guide to Services for Refugees and Migrants in South Africa, 2013](#)

Personal View, Lancet Infectious Diseases: [Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor](#)

Health care providers must register online at <http://new-challenges-in-the-management-of-hiv.msd.com/registration.aspx?PageID=registration> and enter their UNIVADIS username/password to register. If you don't have a UNIVADIS username/password, please send a registration request along with your HPCSA number and email address to [info@univadis.co.za](mailto:info@univadis.co.za).

Please register early to avoid any potential problems with registration.

Satellite Symposium Sponsored by MSD, IAS 2013

## New Challenges in the Management of HIV in 2013 and Beyond

MSD

**CHAIRMAN**  
Datuk Dr. Christopher Lee  
Immediate Past President Malaysia Society for HIV Medicine  
Head of the Medical Department Hospital Sungai Buloh Selangor, Malaysia

**FACULTY**  
David Cooper  
Professor of Medicine, University of New South Wales  
Director, Kirby Institute Sydney, Australia  
Sharon Walmsley  
Director of Clinical Research Immunodeficiency Clinic Professor,  
Department of Medicine University of Toronto Toronto, Canada

**Tuesday, 2 July 2013**  
Live Webcast: 12:30-14:30  
Central African Time (CAT)

Register at: <http://New-Challenges-In-The-Management-of-HIV.msd.com>  
Now available to view on Apple and Android mobile phones and tablets.

**Why Attend?**  
This live 2 hour webcast will review important findings around the challenges of managing ARV long-term toxicity, the pros and cons of NRTI sparing regimens and managing drug-drug interactions.  
You will have an opportunity to listen to leading HIV specialists and ask questions at the conclusion of the presentation.

AGENDA	Tuesday, 2 July 2013	
12:30 – 12:40	Welcome and Opening Remarks	Christopher Lee
12:40 – 13:15	ARV Long-term Toxicity Management	Sharon Walmsley
13:15 – 13:50	NRTI Sparing Regimens: Pros and Cons	David Cooper
13:50 – 14:15	Managing HIV Drug-drug Interactions and How Much Do They Matter?	Christopher Lee
14:15 – 14:25	Discussion	All
14:25 – 14:30	Closing Remarks	Christopher Lee

MSD (Pty) Ltd (Reg. No. 1996/001791/07), Private Bag 3, Halfway House 1685  
© 2013 Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved. MSD, the MSD logo and UNIVADIS are trademarks of Merck & Co., Inc. or its subsidiaries in the USA and other countries.



## Don't let your drug stocks run out

The Stop Stockouts Project (SSP) is collaboration between The Treatment Action Campaign, the Rural Health Advocacy Project, SECTION27, Médecines Sans Frontières, the Rural Doctors' Association of Southern Africa and the SA HIV Clinicians' Society. The goal of the project is to ensure that medical supplies are always available to patients, through collecting data about the causes of stockouts, advocating for strategic solutions to stockouts and working with stakeholders to improve supply chain management. Help the project to gather as much information as possible by reporting drug shortages and stockouts. Click the 'Report Drug Stockouts' button on the top right hand side of the SAHIVSOC website, or go to <http://sahivsoc.org/stockout>



## Upcoming conferences 6th SA AIDS Conference

The [6th SA AIDS conference](#) will be held on the 18th – 21st June 2013 at the Durban ICC. The theme of the conference is "Building on Successes, Integrating Systems" and will bring together

[countries](#)

Presentations from [SANAC's Extended Sex Work Plan Working Group Meeting](#)

## 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention

The [7th IAS Conference \(IAS 2013\)](#) will be held at the Kuala Lumpur Convention Centre, Malaysia from the 30th June – 3rd July 2013. The conference brings together leading scientists, clinicians, public health experts and community leaders to examine the latest developments in HIV-related research.



**IAS 2013**  
7th IAS CONFERENCE ON HIV PATHOGENESIS,  
TREATMENT AND PREVENTION  
30 June - 03 July 2013 - Kuala Lumpur, Malaysia

IAS 2013 will bring together the world's leading scientists, clinicians, implementers, public health experts and community leaders to examine the latest developments in HIV-related research.

Download the IAS 2013 App to access the conference Programme, follow us for news and updates on Facebook, Twitter, LinkedIn and YouTube and get the online scientific coverage provided by NAM aidsmap and Clinical Care Options (CCO) on the IAS 2013 website.

For more information, please visit:  
[www.ias2013.org](http://www.ias2013.org)



## Aspen Pharmacare ARV price reduction

Aspen Pharmacare is pleased to announce a price reduction for Tenarens (TDF 300mg / 3TC / EFV 600mg) from R351,00 to R338,58 (VAT Incl.). If you have any questions about Tenarens or other Aspen Pharmacare antiretrovirals, please contact Lefu Lebelo, HIV Commercial Manager, HIV Division at +27 (0) 11 239-6200.



Integrating systems, and will bring together renowned speakers and delegates with extensive experience in treating and managing HIV clinically, administratively and emotionally. The most recent global developments in managing HIV and AIDS will be presented. For more information go to <http://www.saaids.co.za/>

## 2013 Rural Health Conference

This year the Rural Doctors' Association of Southern Africa will be "Going back to the roots" for their 17th [Rural Health Conference](#), held this year at St Lucia from the 8th – 10th August 2013. The conference will include rural clinical practice, rural rehabilitation, clinical associates, advocacy and health policy, rural health professional education and student involvement. Register online at [www.rudasa.org.za](http://www.rudasa.org.za)

## FIDSAA 2013

The 5th [Federation of Infectious Diseases Societies of Southern Africa Conference](#), themed "Changing Attitudes", will be held at the Champagne Sports Resort in the Drakensberg, on the 10th – 12 October 2013. Early registration and abstract submission (deadline 14 June) is now open, so go to <http://www.fidssa.co.za/default.asp> for more information.

## 7th Annual Workshop on Advanced Clinical Care (AWACC)

The 7th AWACC is scheduled for 26 and 27 September 2013 at the Elangeni hotel in Durban. Early registration will open later this month so keep an eye on the [website](#).

## Society Blog

The Society is developing an on-going blog for its website featuring "voices from the field", and we want to hear from you! Blog entries are informal and should average around 500 words. If you are interested in contributing, please contact Suzanne Nicholson ([sueznicholson@gmail.com](mailto:sueznicholson@gmail.com)) for more information.





## Contact Details for the Southern African HIV Clinicians Society:

**Tel:** (011) 728 7365 | **Fax:** (011) 728 1251

**Email:** [sahivsoc@sahivsoc.org](mailto:sahivsoc@sahivsoc.org) | **Website:** [www.sahivsoc.org](http://www.sahivsoc.org)

**Address:** 112 Algernon Road Norwood

**Post:** Suite 233 Postnet, Killarney Private Bag X2600 Houghton 2041



Have news you'd like to share? Email us at [sahivsoc@sahivsoc.org](mailto:sahivsoc@sahivsoc.org)